EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study

Michael Gold, Joel Schlessinger, Greg J Goodman iD, Steven Dayan, Janet DuBois, Yu-Fang Ling, An-Yi Sheu, Wilson W S Ho, Yin-Chia Chou

Aesthetic Surgery Journal · 2025

DOI: 10.1093/asj/sjaf032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von Michael Gold und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Subcutaneous Fat, Abdominal. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Caliway Biopharmaceuticals, Tech Observer Asia Pacific Pte. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A small-molecule injectable drug, CBL-514, has shown promising efficacy and safety for subcutaneous fat reduction.

Objectives

To further evaluate the efficacy and safety of CBL-514 for abdominal subcutaneous fat reduction.

Methods

In this single-blind, randomized, parallel-group, placebo-controlled Phase 2 trial, 76 participants were randomized (2:1) to receive up to 4 CBL-514 treatments (2 mg/cm2, maximum 600 mg/treatment) or placebo, administered subcutaneously to the abdomen every 4 weeks. Two follow-up visits were conducted at 4 and 8 weeks following final treatment. Changes in abdominal subcutaneous fat thickness and volume were measured by ultrasound. The primary endpoint was the proportion of participants with subcutaneous fat volume loss of ≥150 mL from baseline compared with placebo.

Results

In the intention-to-treat population, a significantly higher proportion of CBL-514-treated participants achieved ≥150 mL subcutaneous fat volume reduction from baseline compared with placebo-treated participants at both follow-up visits. At 8 weeks post final treatment, 69.6% of CBL-514-treated participants lost ≥150 mL subcutaneous fat, compared with none in the placebo group (P < .001). Moreover, 60.9% of participants in the CBL-514 group further achieved the ≥200 mL subcutaneous fat loss threshold. Of the 28 participants in CBL-514 group (n = 50) who lost ≥150 mL subcutaneous fat, 42.9% (12/28 participants) achieved this target after a single treatment. The most common treatment-emergent adverse events were injection site reactions and were of mild-to-moderate severity.

Conclusions

CBL-514 treatment significantly reduced abdominal subcutaneous fat volume with a favorable safety profile. As a noninvasive treatment, CBL-514 could be a new, promising alternative therapy for effective targeted subcutaneous fat reduction. Level of Evidence: 2

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Subcutaneous Fat, AbdominalHumansFemaleSingle-Blind MethodMaleAdultMiddle AgedInjections, SubcutaneousTreatment Outcome

Autor:innen und Institutionen

ORCID-Profile: Greg J Goodman

Förderung

  • Caliway Biopharmaceuticals
  • Tech Observer Asia Pacific Pte. Ltd

Zitieren

APA

Gold, M., Schlessinger, J., Goodman, G. J., Dayan, S., DuBois, J., Ling, Y. F., Sheu, A. Y., Ho, W. W. S., & Chou, Y. C. (2025). Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf032

Vancouver

Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, et al. Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjaf032

BibTeX
@article{Gold2025,
  author = {Gold, Michael and Schlessinger, Joel and Goodman, Greg J and Dayan, Steven and DuBois, Janet and Ling, Yu-Fang and Sheu, An-Yi and Ho, Wilson W S and Chou, Yin-Chia},
  title = {Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study},
  journal = {Aesthetic Surgery Journal},
  year = {2025},
  doi = {10.1093/asj/sjaf032}
}
Kostenlos starten →